Drug Profile

BLR 200

Alternative Names: BLR-200

Latest Information Update: 17 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BLR Bio
Class Anti-inflammatories; Antifibrotics; Antivirals; Hepatoprotectants; Skin disorder therapies
Mechanism of Action Fibroblast activation protein antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Systemic scleroderma
New Molecular Entity Yes

Preclinical Cholangitis; COVID 2019 infections; Interstitial lung diseases; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Peritoneal fibrosis; Pulmonary arterial hypertension; Systemic scleroderma

11 Apr 2024 BLR 200 receives Orphan Drug status for Systemic scleroderma in USA
31 Mar 2023 Preclinical development for Scleroderma in USA (unspecified route) (BLR Bio pipeline, February 2023)
14 Feb 2023 Preclinical trials in Cholangitis in USA (unspecified route) (BLR Bio pipeline, February 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com